Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells

Blood

Volumn 105, Issue 2, 2005, Pages 804-811

  Frelin, Catherine ^b   Imbert, Véronique ^b   Griessinger, Emmanuel ^b   Peyron, Annie Claude ^b   Rochet, Nathalie ^b   Philip, Patrick ^b   Dageville, Christian ^b   Sirvent, Anne ^b   Hummelsberger, Michaël ^b   Bérard, Etienne ^b   Dreano, Michel ^b   Sirvent, Nicolas ^b   Peyron, Jean François ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AS 602868; CASPASE; CD34 ANTIGEN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; I KAPPA B KINASE; I KAPPA B KINASE 2; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHUK PROTEIN, HUMAN; ENZYME INHIBITOR; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOID LEUKEMIA; PRIORITY JOURNAL; ACUTE DISEASE; CELL CULTURE; CHILD; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PHOSPHORYLATION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CHILD; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; I-KAPPA B KINASE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 19944427042     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1463     Document Type: Article

References (34)

1. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
2. Löwenberg B, Downing J, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
3. Jordan C. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16:559-562.
4. Guzman M, Neering S, Upchurch D, et al. Nuclear factor-κB is constitutively activated in primitive human kacute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
5. Staudt L. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
6. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphobiastic leukemia cells. Leukemia. 2000;14:399-402.
7. Karin M, Cao Y, Greten F, Li Z. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
8. Foo S, Nolan G. NF-κB to the rescue. Trends Genet. 1999;15:229-235.
9. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 1996;274:787-789.
10. Wang CY, Mayo MW, Baldwin AS Jr. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
11. Bottero V, Busuttil V, Loubat A, et al. Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 2001;61:7785-7791.
12. Pahl H. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853-6866.
13. Karin M. How NF-kB is activated: the role of the IkB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
14. Busuttil V, Bottero V, Frelin C, et al. Blocking NF-κB activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector. Oncogene. 2002;21:3213-3224.
15. Yamamoto Y, Gaynor R. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-142.
16. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med. 2002;8:S49-S54.
17. Frelin C, Imbert V, Griessinger M, Loubat A, Dreano M, Peyron J-F. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic T cells. Oncogene. 2003;22:8187-8194.
18. Vindelov L, Christensen I, Nissen N. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983;3:323-327.
19. Bottero V, Imbert V, Frelin C, Formento J, Peyron JF. Monitoring NF-kappaB transactivation potential via real-time PCR quantification of IkappaB-alpha gene expression. Mol Diagn. 2003;7:187-194.
20. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science. 1997;278:860-866.
21. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
22. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925-6937.
23. Baumgartner B, Weber M, Quirling M, et al. Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts. Leukemia. 2002;16:2062-2071.
24. Hengartner M. The biochemistry of apoptosis. Nature. 2000;407:770-776.
25. Deveraux Q, Reed J. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239-252.
26. Cheng Q, Lee H, Li Y, Parks T, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene. 2000;19:4936-4940.
27. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
28. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol. 1998;51:1-7.
29. Orlowski R, Stinchcombe T, Mitchell B, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
30. Terpstra W, Ploemacher R, Prins A, et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood. 1996;88:1944-1950.
31. Guzman M, Swiderski C, Howard D, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99:16220-16225.
32. Lumkul R, Gorin N, Malehorn M, et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia. 2002;16:1818-1826.
33. Wendel H, de Stanchina E, Fridman J, et al. Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature. 2004;428:332-337.
34. Davis R, Brown K, Siebenlist U, Staud L. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861-1874.